Domainex has invested in the Creoptix WAVEdelta platform which uses the biophysical technique of Grating-Coupled Interferometry (GCI). GCI is analogous to Surface Plasmon Resonance (SPR). In both techniques, the target protein is immobilised onto specialised sensor chips and the passage of analytes over the chip surface are monitored as time-dependent changes in refractive index, which can indicate bi-molecular interactions.
Technology at Domainex
Grating Coupled Interferometry (GCI) and Surface Plasmon Resonance (SPR) are techniques that detects how two molecules bind in real time by measuring tiny changes in refractive index that are obtained from mass changes near the sensor surface when a bi-molecular interaction occurs.
GCI vs SPR
Where GCI and SPR differ is that SPR detect a localised area of the chip surface whereas GCI samples the entire chip surface. GCI is therefore able to detect more binding events which enhances its sensitivity relative to SPR. Additionally, because the evanescent field does not penetrate as deep into the sample with GCI, there is less disturbance by bulk refractive index changes. GCI technology has proven application in fragment screening and to support subsequent hit-to-lead and lead optimisation stages of drug discovery. As the assay is label-free, homogenous, flow-based and kinetically read, it is ideally suited to measuring compound binding kinetics. The sensitivity and versatility of the WAVE system enables a wide variety of matrices to be used.